Short Interest in Universe Pharmaceuticals INC (NASDAQ:UPC) Rises By 1,406.0%

Universe Pharmaceuticals INC (NASDAQ:UPC) was the recipient of a large increase in short interest during the month of May. As of May 15th, there was short interest totaling 11,506 shares, an increase of 1,406.0% from the April 30th total of 764 shares. Based on an average daily volume of 22,039 shares, the short-interest ratio is currently 0.5 days. Approximately 4.8% of the shares of the company are short sold.

Universe Pharmaceuticals Price Performance

Shares of NASDAQ UPC traded up $0.70 during mid-day trading on Friday, reaching $3.55. 28,338 shares of the company traded hands, compared to its average volume of 12,851. Universe Pharmaceuticals has a fifty-two week low of $2.00 and a fifty-two week high of $11.00. The stock has a fifty day simple moving average of $2.85 and a 200-day simple moving average of $3.39.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Universe Pharmaceuticals in a research report on Friday, May 1st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

About Universe Pharmaceuticals

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.